Digital health company NeuroRPM has received clearance from the US Food and Drug Administration (FDA) for its artificial intelligence (AI)-powered remote monitoring app for Parkinson’s disease.
The NeuroRPM technology monitors the Parkinson’s disease symptoms of bradykinesia, tremor and dyskinesia continuously and passively with AI and the Apple Watch.
With advanced and comprehensive monitoring capabilities for Parkinson’s added to the wearable device, the technology allows the full range of disease symptoms to be tracked on a day-to-day basis.
NeuroRPM president Atila Omer said: “We are thrilled to be on the new frontier of digital health with NeuroRPM. By leveraging the power of Apple Watch, we are transforming the way individuals with Parkinson’s disease understand their health, enabling care providers to make more informed clinical decisions, which will lead to better health outcomes.
“We are honoured to help drive this revolution in healthcare.”
The technology comprises proprietary algorithms that are integrated into an Apple Watch app.
This app passively gathers information during everyday use and helps to continuously monitor symptoms and health metrics for Parkinson’s disease.
Available by prescription, the NeuroRPM technology only uses Apple Watch information that users have chosen to share with the app.
Said to be the culmination of years of studies and technical research, NeuroRPM represents a major advancement in Parkinson’s disease management.
NeuroRPM co-founder and University of Maryland Functional Neurosurgery director Dr Alexander Ksendzovsky said: “This technology will allow for unprecedented insights into the symptoms of Parkinson’s disease including bradykinesia, tremor, and dyskinesia, using critical health and wellness data from Apple Watch.”